Edwards Lifesciences Corporation (NYSE:EW) Analyst Rating Consensus

Edwards Lifesciences Corporation (NYSE:EW) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1.68 by 17 Brokerage Firm. 10 Wall Street Firms have rated the stock as a strong buys. 2 stock experts have also suggested a buy rating. 5 Brokerage Firms have advised hold.

Other Equity analysts have also commented on the company shares. Guggenheim Securities initiates coverage on Edwards Lifesciences Corporation (NYSE:EW).The analysts at the brokerage house have a current rating of Neutral on the shares. The rating by the firm was issued on June 9, 2016.

Edwards Lifesciences Corporation (NYSE:EW): According to 14 Analysts, The short term target price has been estimated at $ 117.14.The target price could deviate by a maximum of $9.26 from the forecast price. In the near term, the target price could hit a high of $132 and a low of $ 100.

Edwards Lifesciences Corporation (NYSE:EW) witnessed a decline in the market cap on Tuesday as its shares dropped 0.6% or 0.59 points. After the session commenced at $99.44, the stock reached the higher end at $99.9 while it hit a low of $98.35. With the volume soaring to 1,246,992 shares, the last trade was called at $98.57. The company has a 52-week high of $112. The company has a market cap of $20,873 million and there are 211,762,740 shares in outstanding. The 52-week low of the share price is $62.53.

Edwards Lifesciences Corp. has lost 2.36% in the last five trading days and dropped 0.54% in the last 4 weeks. Edwards Lifesciences Corp. is up 14.28% in the last 3-month period. Year-to-Date the stock performance stands at 24.8%.

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patients diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patients cardiovascular function in the hospital setting. Patients in the hospital setting, including high-risk patients in the operating room or intensive care unit, are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Companys products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.